Study shows MS treatments delay progression of the disease

January 17, 2019
An international study finds multiple sclerosis treatments have long-term benefits, and that early treatment is important.

The Royal Melbourne Hospital and University of Melbourne-led study is the first to provide evidence that the currently available therapies can delay progression of disability in multiple sclerosis. The international study used data from 1555 patients, from 68 neurological clinics across 21 countries. It showed that early treatment – particularly within five years of onset – delayed the secondary progressive stage of MS, which is characterized by an ongoing increase of disability.

The results of the study were published in the journal JAMA.

MS Focus Lending Library


Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Study uncovers potential risks of common MS treatment


Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more

Study: Molecule may slow progression of MS

November 15, 2019

Results could lead to the development of a new generation of therapies to treat this autoimmune disease.
Learn more